proxyvotesnow.com

Home › Companies › Vir Biotechnology, Inc. › 2025-2026

Vir Biotechnology, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Vir Biotechnology, Inc.’s Form 8-K, filed 2026-05-28 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 5Ballot items
  • 261Asset managers
  • 1,626Fund votes
  • 2026-05-26Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Vir Biotechnology, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vir Biotechnology, Inc.

These tallies are Vir Biotechnology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vir Biotechnology, Inc. — official shareholder meeting results, meeting held 2026-05-26
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Robert More, MBA 114,856,835---- 6,833,09616,677,343 Majority: yes
Elect Director: Janet Napolitano, J.D. 67,235,175---- 54,454,75616,677,343 Majority: yes
Elect Director: Elliott Sigal, M.D., Ph.D. 115,030,681---- 6,659,25016,677,343 Majority: yes
Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. 108,453,96311,863,4051,372,563 --16,677,343 Majority: yes
Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's in 137,048,756153,8361,164,682 --0 Majority: yes

This meeting is also recorded here as 2026-05-25; both records come from the same filing, so the date should be checked against it.

Source: Vir Biotechnology, Inc., Form 8-K, filed with the SEC on 2026-05-28 — read the filing on EDGAR.

How asset managers voted at the Vir Biotechnology, Inc. 2025-2026 meeting

Each item below shows how the 261 asset managers that disclosed a Vir Biotechnology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 108,453,963AGAINST: 11,863,405

Vir Biotechnology, Inc.’s own tally for this item (“Proposal 2. Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”): 108,453,963 for, 11,863,405 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 168,651,974 outstanding shares: 64% for, 7% against (71% of the company cast a for/against vote).

The 260 asset managers below cast 90% of the shares they voted on this item FOR (95,590,909 for, 10,209,350 against).

FOR 90%10%
FOR: 95,590,909 (90.2%)AGAINST: 10,209,350 (9.6%)ABSTAIN: 132,943 (0.1%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Vir Biotechnology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock17,281,89633,031 00For
Vanguard15,655,05916,136 80For
ARCH Venture Management, LLC12,916,6630 00For
SB INVESTMENT ADVISERS (UK) LTD10,948,0930 00For
State Street6,672,49930,422 00For
Fidelity2,343,0792,601,872 00Against
Ballentine Partners, LLC2,666,1730 00For
GEODE CAPITAL MANAGEMENT, LLC2,487,9500 00For
Charles Schwab2,198,7270 00For
Soleus Capital Management, L.P.2,002,0000 00For
PICTET ASSET MANAGEMENT SA1,325,1100 00For
Candriam S.C.A.01,135,763 00Against
Point721,114,7060 00For
Ensign Peak Advisors, Inc1,070,8120 00For
Dimensional01,042,808 00Against
Nuveen1,018,9980 00For
TIAA991,2800 00For
Northern Trust909,15314,399 00For
JACOBS LEVY EQUITY MANAGEMENT, INC755,2230 00For
Hudson Bay Capital Management LP722,6540 00For
ADAR1 Capital Management, LLC650,9890 00For
Avidity Partners Management LP0650,000 00Against
MELLON INVESTMENTS Corp603,9200 00For
American Century0592,464 00Against
JPMorgan0581,078 00Against

Showing the 25 largest of 260 asset managers. See all 260 in the interactive database.

2. To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Elliott Sigal, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 115,030,681WITHHELD: 6,659,250

Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 115,030,681 for, 6,659,250 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 168,651,974 outstanding shares: 68% for, 4% withheld (72% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (40,478,157 for, 0 against).

FOR 96%
FOR: 40,478,157 (96.5%)ABSTAIN: 1,484,660 (3.5%)
Largest asset managers voting on “To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholder” at Vir Biotechnology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,741,9320 29,5100For
BlackRock12,319,2670 00For
State Street4,718,3940 6,4400For
Fidelity2,343,0790 580,8730For
Charles Schwab1,027,7600 00For
TIAA991,2800 00For
Dimensional00 730,3670Abstain
JPMorgan581,0780 00For
Delaware/Macquarie500,0000 00For
Columbia Threadneedle364,3420 00For
American Century295,6660 00For
Nationwide264,0050 00For
Jackson National191,8730 27,1830For
Invesco208,5750 00For
Equitable130,3680 64,8300For
GuideStone155,8000 00For
QUANTITATIVE MASTER SERIES LLC148,5520 00For
Thrivent112,2150 00For
Prudential/PGIM99,0170 12,1300For
BNY Mellon96,5220 00For
Principal93,5270 00For
Global X86,7210 00For
ProShares85,6710 00For
Empower84,4050 00For
Lincoln Financial76,7810 5,5660For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

3. To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Janet Napolitano, J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

55% Majority: yes · of votes cast

FOR 55%WITHHELD 45%
FOR: 67,235,175WITHHELD: 54,454,756

Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Janet Napolitano, J.D.”): 67,235,175 for, 54,454,756 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 168,651,974 outstanding shares: 40% for, 32% withheld (72% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (14,439,496 for, 0 against).

FOR 34%ABSTAIN 66%
FOR: 14,439,496 (34.4%)ABSTAIN: 27,523,316 (65.6%)
Largest asset managers voting on “To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholder” at Vir Biotechnology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard9,431,5490 5,339,8890For
BlackRock00 12,319,2670Abstain
State Street4,711,0750 13,7590For
Fidelity00 2,923,9520Abstain
Charles Schwab00 1,027,7600Abstain
TIAA00 991,2800Abstain
Dimensional00 730,3670Abstain
JPMorgan00 581,0780Abstain
Delaware/Macquarie00 500,0000Abstain
Columbia Threadneedle00 364,3420Abstain
American Century00 295,6660Abstain
Nationwide00 264,0050Abstain
Jackson National00 219,0560Abstain
Invesco208,5750 00For
Equitable00 195,1980Abstain
GuideStone00 155,8000Abstain
QUANTITATIVE MASTER SERIES LLC00 148,5520Abstain
Thrivent00 112,2150Abstain
Prudential/PGIM00 111,1470Abstain
BNY Mellon00 96,5220Abstain
Principal00 93,5270Abstain
Global X00 86,7210Abstain
ProShares00 85,6710Abstain
Empower00 84,4050Abstain
Lincoln Financial61,0000 21,3470For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Robert More, MBA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 114,856,835WITHHELD: 6,833,096

Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Robert More, MBA”): 114,856,835 for, 6,833,096 withheld, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 168,651,974 outstanding shares: 68% for, 4% withheld (72% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (40,478,156 for, 0 against).

FOR 96%
FOR: 40,478,156 (96.5%)ABSTAIN: 1,484,661 (3.5%)
Largest asset managers voting on “To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholder” at Vir Biotechnology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,741,9310 29,5110For
BlackRock12,319,2670 00For
State Street4,718,3940 6,4400For
Fidelity2,343,0790 580,8730For
Charles Schwab1,027,7600 00For
TIAA991,2800 00For
Dimensional00 730,3670Abstain
JPMorgan581,0780 00For
Delaware/Macquarie500,0000 00For
Columbia Threadneedle364,3420 00For
American Century295,6660 00For
Nationwide264,0050 00For
Jackson National191,8730 27,1830For
Invesco208,5750 00For
Equitable130,3680 64,8300For
GuideStone155,8000 00For
QUANTITATIVE MASTER SERIES LLC148,5520 00For
Thrivent112,2150 00For
Prudential/PGIM99,0170 12,1300For
BNY Mellon96,5220 00For
Principal93,5270 00For
Global X86,7210 00For
ProShares85,6710 00For
Empower84,4050 00For
Lincoln Financial76,7810 5,5660For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

5. TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 137,048,756AGAINST: 153,836

Vir Biotechnology, Inc.’s own tally for this item (“Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 137,048,756 for, 153,836 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 168,651,974 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (41,954,765 for, 223 against).

FOR 99.9%
FOR: 41,954,765 (100.0%)AGAINST: 223 (0.0%)ABSTAIN: 7,828 (0.0%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY” at Vir Biotechnology, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard14,771,4340 80For
BlackRock12,319,2670 00For
State Street4,724,611223 00For
Fidelity2,923,9520 00For
Charles Schwab1,027,7600 00For
TIAA991,2800 00For
Dimensional730,3670 00For
JPMorgan581,0780 00For
Delaware/Macquarie500,0000 00For
Columbia Threadneedle364,3420 00For
American Century295,6660 00For
Nationwide264,0050 00For
Jackson National219,0560 00For
Invesco208,5750 00For
Equitable195,1980 00For
GuideStone155,8000 00For
QUANTITATIVE MASTER SERIES LLC148,5520 00For
Thrivent112,2150 00For
Prudential/PGIM111,1470 00For
BNY Mellon96,5220 00For
Principal93,5270 00For
Global X86,7210 00For
ProShares85,6710 00For
Empower84,4050 00For
Lincoln Financial82,3470 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Largest Vir Biotechnology, Inc. shareholders voting in 2025-2026

Ranked by the number of Vir Biotechnology, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 168,651,974 shares outstanding at the time of that meeting.

Top Vir Biotechnology, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 10.27%
2Vanguard 9.29%
3ARCH Venture Management, LLC 7.66%
4SB INVESTMENT ADVISERS (UK) LTD 6.49%
5State Street 3.97%
6Fidelity 2.93%
7Ballentine Partners, LLC 1.58%
8GEODE CAPITAL MANAGEMENT, LLC 1.48%
9Charles Schwab 1.30%
10Soleus Capital Management, L.P. 1.19%

Reported Vir Biotechnology, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Vir Biotechnology, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 10.67% 13F
SVF Endurance (Cayman) Ltd. 7.78% DEF14A
Entities affiliated with ARCH Venture Partners, L.P. 7.66% DEF14A
Vanguard Group 7.44% 13F
SB Investment Advisers (UK) Limited 6.49% 13G
Glaxo Group Limited 5.07% DEF14A
State Street 4.23% 13F
Goldman Sachs 1.93% 13F
Morgan Stanley 1.59% 13F
Geode Capital 1.58% 13F

Percentages above are of 168,651,974 shares outstanding, as reported by Vir Biotechnology, Inc. on its Form 10-Q dated 2026-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vir Biotechnology, Inc.’s 10-Q dated 2026-04-29. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Vir Biotechnology, Inc.'s shareholder meeting held 2026-05-26, in the 2025-2026 proxy season, 261 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,626 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Vir Biotechnology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-28.

Vir Biotechnology, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).